{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Exelixis, Inc. technically bullish or bearish?
As of October 24, 2025, Exelixis, Inc. is in a mildly bearish trend, with mixed technical indicators, having outperformed the S&P 500 year-to-date and over the past year, but underperformed in the short term.
Exelixis Stock Forms Death Cross, Signaling Potential Bearish Trend Ahead
Exelixis, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While the stock has outperformed the S&P 500 over the past year, recent weekly performance has declined. Investors are advised to monitor these technical signals as market dynamics evolve in the biotechnology sector.
Is Exelixis, Inc. technically bullish or bearish?
As of October 24, 2025, Exelixis, Inc. shows a mildly bearish technical trend, indicated by bearish momentum in the MACD, KST, and moving averages, despite a bullish weekly RSI and mixed signals from Bollinger Bands.
Is Exelixis, Inc. technically bullish or bearish?
As of October 24, 2025, Exelixis, Inc. shows a mildly bearish trend despite outperforming the S&P 500 year-to-date and over the past year, with recent indicators suggesting a shift in momentum.
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Performance
Exelixis, Inc. has adjusted its valuation, with a P/E ratio of 17 and a price-to-book value of 5.51. The company demonstrates strong operational performance, reflected in its high ROCE of 74.07% and ROE of 32.08%. Over the past year, Exelixis has outperformed the S&P 500.
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 5.51. The company demonstrates strong performance metrics, including a 20.39% year-to-date return and a 52.78% return over the past year, highlighting its competitive position in the pharmaceuticals sector.
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 5.51. The company exhibits strong financial metrics, including a ROCE of 74.07% and a ROE of 32.08%, positioning it favorably against industry peers. Its stock performance has outpaced the S&P 500 year-to-date.
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
Exelixis, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 17 and a strong return on capital employed of 74.07%. Compared to peers, it maintains a favorable valuation profile. The company has outperformed the S&P 500 with a year-to-date return of 20.42% and a 49.46% return over the past year.
Is Exelixis, Inc. technically bullish or bearish?
As of July 29, 2025, Exelixis, Inc. has a mildly bullish technical trend, supported by daily moving averages and a bullish monthly MACD, despite mixed signals from weekly indicators and a year-to-date return of 21.47% compared to the S&P 500's 12.22%.
Is Exelixis, Inc. overvalued or undervalued?
As of July 28, 2025, Exelixis, Inc. is considered attractively valued with a P/E ratio of 17, an EV to EBITDA of 12.68, a PEG ratio of 0.08, strong returns on capital and equity, and a 1-year return of 50.82%, outperforming the S&P 500's 17.14%.
Is Exelixis, Inc. overvalued or undervalued?
As of May 3, 2024, Exelixis, Inc. is considered fairly valued with a shift from very attractive to attractive, featuring a P/E ratio of 17, an EV to EBITDA of 12.68, a competitive PEG ratio of 0.08, and a remarkable 1-year return of 95.36%, significantly outperforming the S&P 500's 10.26%.
Is Exelixis, Inc. technically bullish or bearish?
As of May 1, 2024, Exelixis, Inc. has a mildly bullish technical trend, supported by positive MACD, Bollinger Bands, and KST indicators, though the On-Balance Volume shows a slightly bearish trend.
Who are in the management team of Exelixis, Inc.?
As of March 2022, the management team of Exelixis, Inc. includes Dr. Stelios Papadopoulos (Independent Chairman), Dr. Michael Morrissey (President and CEO), and several Independent Directors: Dr. Charles Cohen, Mr. Carl Feldbaum, Dr. Maria Freire, Dr. Alan Garber, and Dr. Vincent Marchesi. This team is responsible for the company's strategic direction and management.
What does Exelixis, Inc. do?
Exelixis, Inc. is a mid-cap biopharmaceutical company focused on developing and commercializing cancer treatments. As of March 2025, it reported net sales of $555 million and a net profit of $160 million.
How big is Exelixis, Inc.?
As of Jun 18, Exelixis, Inc. has a market capitalization of $11.28 billion, with net sales of $2.30 billion and net profit of $643.57 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
